REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 155 filers reported holding REVANCE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,129,066 | -70.2% | 1,144,644 | -34.2% | 0.00% | -66.7% |
| Q2 2023 | $44,062,230 | +24.6% | 1,740,902 | +58.5% | 0.01% | +12.5% |
| Q1 2023 | $35,375,921 | +58.1% | 1,098,290 | -9.4% | 0.01% | +60.0% |
| Q4 2022 | $22,370,936 | -27.3% | 1,211,860 | +6.3% | 0.01% | -28.6% |
| Q3 2022 | $30,774,000 | +168.6% | 1,139,808 | +37.5% | 0.01% | +133.3% |
| Q2 2022 | $11,456,000 | -10.5% | 828,925 | +26.3% | 0.00% | 0.0% |
| Q1 2022 | $12,803,000 | -2.7% | 656,556 | -18.5% | 0.00% | 0.0% |
| Q4 2021 | $13,155,000 | -20.6% | 806,032 | +35.5% | 0.00% | -25.0% |
| Q3 2021 | $16,568,000 | +20.1% | 594,700 | +27.8% | 0.00% | +33.3% |
| Q2 2021 | $13,796,000 | +10.2% | 465,436 | +4.0% | 0.00% | 0.0% |
| Q1 2021 | $12,514,000 | +9.3% | 447,715 | +10.8% | 0.00% | 0.0% |
| Q4 2020 | $11,452,000 | +0.6% | 404,126 | -10.7% | 0.00% | 0.0% |
| Q3 2020 | $11,379,000 | -16.9% | 452,616 | -19.3% | 0.00% | -25.0% |
| Q2 2020 | $13,696,000 | +26.5% | 560,875 | -23.3% | 0.00% | 0.0% |
| Q1 2020 | $10,827,000 | +518.3% | 731,534 | +577.9% | 0.00% | – |
| Q4 2019 | $1,751,000 | +80.3% | 107,908 | +44.4% | 0.00% | – |
| Q3 2019 | $971,000 | +39.5% | 74,715 | +39.2% | 0.00% | – |
| Q2 2019 | $696,000 | -60.7% | 53,685 | -52.3% | 0.00% | -100.0% |
| Q1 2019 | $1,772,000 | +123.2% | 112,458 | +185.0% | 0.00% | – |
| Q4 2018 | $794,000 | -61.7% | 39,462 | -52.7% | 0.00% | -100.0% |
| Q3 2018 | $2,072,000 | -44.6% | 83,370 | -38.8% | 0.00% | 0.0% |
| Q2 2018 | $3,739,000 | +105.7% | 136,242 | +130.8% | 0.00% | – |
| Q1 2018 | $1,818,000 | +91.6% | 59,021 | +122.3% | 0.00% | – |
| Q4 2017 | $949,000 | -81.4% | 26,546 | -85.6% | 0.00% | -100.0% |
| Q3 2017 | $5,093,000 | +7.4% | 184,880 | +2.9% | 0.00% | 0.0% |
| Q2 2017 | $4,743,000 | -58.4% | 179,657 | -67.3% | 0.00% | -66.7% |
| Q1 2017 | $11,412,000 | +35.4% | 548,650 | +34.7% | 0.00% | +50.0% |
| Q4 2016 | $8,430,000 | +22.2% | 407,250 | -4.3% | 0.00% | 0.0% |
| Q3 2016 | $6,900,000 | +19.3% | 425,625 | +0.1% | 0.00% | 0.0% |
| Q2 2016 | $5,782,000 | +10.4% | 425,179 | +41.7% | 0.00% | 0.0% |
| Q1 2016 | $5,239,000 | -51.4% | 300,056 | -5.0% | 0.00% | -33.3% |
| Q4 2015 | $10,788,000 | -5.0% | 315,826 | -17.2% | 0.00% | -25.0% |
| Q3 2015 | $11,353,000 | +14.5% | 381,485 | +23.1% | 0.00% | +33.3% |
| Q2 2015 | $9,912,000 | +14.9% | 309,938 | -25.5% | 0.00% | 0.0% |
| Q1 2015 | $8,623,000 | +26.4% | 415,965 | +3.3% | 0.00% | +50.0% |
| Q4 2014 | $6,823,000 | -17.0% | 402,755 | -5.3% | 0.00% | -33.3% |
| Q3 2014 | $8,224,000 | -45.0% | 425,445 | -3.2% | 0.00% | -40.0% |
| Q2 2014 | $14,950,000 | +95.2% | 439,702 | +80.9% | 0.01% | +66.7% |
| Q1 2014 | $7,658,000 | – | 243,103 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 4,405,039 | $118,936,000 | 9.40% |
| Essex Woodlands Management, Inc. | 457,085 | $12,341,000 | 5.10% |
| Evolutionary Tree Capital Management, LLC | 191,868 | $5,180,000 | 4.98% |
| Ghost Tree Capital, LLC | 390,000 | $10,530,000 | 2.96% |
| Antara Capital LP | 4,069,400 | $109,874,000 | 2.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 896,754 | $24,212,000 | 1.40% |
| Jericho Capital Asset Management L.P. | 714,000 | $19,278,000 | 1.22% |
| Antara Capital LP | 1,600,000 | $43,200,000 | 1.14% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 120,000 | $3,240,000 | 1.04% |
| TANG CAPITAL MANAGEMENT LLC | 287,500 | $7,763,000 | 0.95% |